

*To Our Shareholders, Employees & Partners:*

As the COVID-19 pandemic endures, we remain hopeful as America's vaccinations continue to rise. We are carefully monitoring the situation to maintain the health and safety of our employees, while keeping our business operational and secure – especially as COVID-19 variants cause a spike in new cases across the globe.

Although last year was one of Cumberland's most challenging, we are pleased to announce the results of our **2020 Sustainability Report**, outlining our activities pertaining to environmental, social and governance (ESG) matters. As the largest biopharmaceutical company founded and headquartered in the Mid-South, we hold ourselves to the highest standards of ethical practices and understand the importance of addressing our impact on our constituents, the community and the environment. Some highlights of this report include:

- Provided nearly 2.5 million doses of our products for patients
- Safely disposed of over 4,000 pounds of expired or damaged goods
- No products recalled and no clinical trials terminated due to failure to practice good clinical standards
- No Company brands listed on the FDA's MedWatch Safety Alerts for Human Medical Products
- Serialized all commercial products distributed in the U.S. to help prevent counterfeit drugs from entering the market under the Cumberland brand
- Engaged with the community, hosted a special fundraising event to provide food & shelter for the needy
- Invested in our employees through education programs, development initiatives and recognition awards

During the second quarter of 2021, our portfolio of FDA-approved brands delivered combined revenues of \$9.1 million. Net income for the period was \$1.2 million or \$.08 a share. We ended the quarter with just under \$90 million in total assets, \$41 million in liabilities and \$48 million of shareholders' equity.

Although we faced continued headwinds due to COVID-19, Cumberland was able to weather the pandemic and counter its negative effects due to our diversified product portfolio – with Kristalose having an especially strong performance in the second quarter.

Other recent Company developments include:

- Released a dossier of case studies that outline the success of our **Vibativ**<sup>®</sup> product in treating secondary bacterial infections in COVID-19 patients
- Appointed **John Hamm** as the new Senior Director of Finance & Accounting and Chief Financial Officer
- Received formal notice from the U.S. Small Business Administration of forgiveness for our \$2.2 million **Paycheck Protection Program loan**
- Prepared for the launch our FDA-approved **RediTrex**<sup>®</sup> line of injectable methotrexate products nationally in late September 2021

I would like to recognize and thank our team for their dedication as we work to advance patient care through the delivery of high-quality medicines. We look forward to continuing the supply of our products, building a differentiated portfolio of brands and growing our business during the remainder of the year and beyond.

All the best,



August 2021